Three New Media Briefings Added To BIO's CEO & Investor Conference

WASHINGTON, D.C. (February 21, 2003) - Three groups of industry experts will hold press briefings during the Biotechnology Industry Organization’s (BIO) CEO & Investor Conference, February 25-27 at the Waldorf=Astoria in New York City.

Drug Development Media Briefing

Bruce Jenett, co-chair of Heller Ehrman’s Life Sciences National Practice Group
Roger M. Perlmutter, M.D., Ph.D., executive vice president for R&D, Amgen
Richard DiMarchi, Ph.D., group vice president, Eli Lilly and Company
Seán P. Lance, CEO and chairman of the board, Chiron
Vicki L. Sato, Ph.D., president, Vertex Pharmaceuticals, Inc.

WHAT: Follow-up discussion from the plenary panel discussion on "The Challenge of Drug Development: Winning Strategies for Building and Maintaining Successful Pipelines."

WHEN: Wednesday, February 26, 9:45-10:30 a.m.

WHERE: Waldorf=Astoria, Park Avenue South

Industrial Biotechnology Media and Analyst Briefing - The Third Wave of Biotechnology

Laura A. Berezin, partner, Cooley Godward LLP
Brent Erickson, vice president industrial and environmental, BIO
Roger E. Wyse, Ph.D., managing director, Burrill & Company
Jean-Jacques Bienaimé, CEO and president, Genencor International
John P. Ranieri, vice president bio-based materials, DuPont
Jonathan S. Dordick, Howard P. Isermann Professor and Chairman, Department of Chemical Engineering, Rensselaer Polytechnic Institute

WHAT: This briefing will discuss how industrial biotechnology is rapidly transforming the way chemicals and pharmaceuticals are made and how this growing wave will lift not only biotechnology companies but other industries as well. Analysts estimate that by 2010 industrial biotechnology will impact at least 20 percent of the worldwide bulk and fine chemical markets. This could add up to as much as $280 billion.

WHEN: Wednesday, February 26, 10:30 a.m. - noon

WHERE: Waldorf=Astoria, Gramercy Room, 18th floor

Genetic Testing Media Briefing

John Rowe, M.D., president and CEO, Aetna Health Plans
James Robinson, Ph.D., associate professor, Health Economics, University of California- Berkeley
Paul Billings, M.D., Ph.D., vice president, Wipro, Inc.
Robert Cook-Deegan, M.D., director of the Center for Genome Ethics, Law, and Policy, Duke University

WHAT: Follow-up discussion from the plenary panel session "How Will Health Plans Treat Genetic Testing: The Distance Between Diagnostics and Therapy."

WHEN: Thursday, February 27, 9:45-10:30 a.m.

WHERE: Waldorf=Astoria, Park Avenue South

For more information on the BIO CEO & Investor Conference, please visit Onsite press registration is complimentary for credentialed members of the news media. Only reporters and editors working full-time for print or broadcast news organizations may register onsite with valid, current media credentials (i.e. picture identification from the employing news organization). Freelance journalists and web-based publications may not register onsite.

BIO represents more than 1,000 biotechnology companies, academic institutions, state biotechnology centers and related organizations in all 50 U.S. states and 33 other nations. BIO members are involved in the research and development of health-care, agricultural, industrial and environmental biotechnology products.

# # #